List of expiration dating of drug patents liquidating trust 2016
Although the EU has defined a period of 10 years data exclusivity, this has been revised at the latest review of pharmaceutical EU legislation to the following:10 years if the reference product is centrally approved or application to the centralized procedure has been made before 20 November 2005.Or eight years data exclusivity 2 1 formula if a full dossier is submitted on or after 30 October 2005 via national procedure or 20 November 2005 via centralized procedure .European patents, granted by the European Patent Office (Munich) may have effect in up to 18 European countries (Austria, Belgium, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Liechtenstein, Luxembourg, Monaco, Netherlands, Portugal, Spain, Sweden, Switzerland, United Kingdom).Eurasian patents granted by the Eurasian Patent Office (Moscow), which have effect in 9 countries (Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Republic of Moldova, Russian Federation, Tajikistan, Turkmenistan).However, the European Patent Office warns that the information provided is not exhaustive, often refers to published patent applications only and that this service cannot be considered as a complete and official source of patent information.The ARIPO patents granted by the Office of the African Regional Industrial Property Organization (ARIPO, Harare) may have effect in 14 African countries (Botswana, Gambia, Ghana, Kenya, Lesotho, Malawi, Sierra Leone, Somalia, Sudan, Swaziland, Uganda, United Republic of Tanzania, Zambia, Zimbabwe).Therefore, looking for patents related to a specific drug is a huge task since a drug may be protected by dozens of patents in different countries.A pharmaceutical company which owns an invention, either through its own R&D or in-licensing of patents from other inventors (i.e.
Data mainly originates from the European Patent Office website, which provides patent data originating from about 64 patent offices, including regional patent offices (Argentina, ARIPO, Philippines, Poland, Romania, Russia, Singapore, Slovakia, Slovenia, South Africa, Turkey, Vietnam, Yugoslavia).
The biosimilars market earned revenue of approximately US2 million in 2010, according to Frost and Sullivan.
However, despite estimates that the market will reach approximately US,987 million by 2017, the biosimilars industry is not for the faint hearted.
Considerable investment is required to manufacture and get a biosimilar to market, and with such complex molecules failure can occur at any stage of the development. What you need to know about Biosimilar Medicinal Products. Permission granted to reproduce for personal and non-commercial use only.
Despite this, with a compound annual growth rate of 56.7% expected from 2010 to 2017 many companies – both originator and generics alike – are finding the sector hard to resist. European Commission, Enterprise and Industry Directorate-General. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher.